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Acute Inhibition of MEK Suppresses Congenital
Melanocytic Nevus Syndrome in a Murine Model
Driven by Activated NRAS and Wnt Signaling
Jeffrey S. Pawlikowski1,2,11, Claire Brock1,2, Sheau-Chiann Chen3, Lara Al-Olabi4, Colin Nixon2,
Fiona McGregor2, Simon Paine4, Estelle Chanudet5, Wendy Lambie2, William M. Holmes6, James M. Mullin6,
Ann Richmond7,8, Hong Wu9, Karen Blyth2, Ayala King1, Veronica A. Kinsler4,10 and Peter D. Adams1,2
Congenital melanocytic nevus (CMN) syndrome is the association of pigmented melanocytic nevi with
extra-cutaneous features, classically melanotic cells within the central nervous system, most frequently caused by
a mutation of NRAS codon 61. This condition is currently untreatable and carries a signiﬁcant risk of melanoma
within the skin, brain, or leptomeninges. We have previously proposed a key role for Wnt signaling in the
formation of melanocytic nevi, suggesting that activated Wnt signaling may be synergistic with activated NRAS in
the pathogenesis of CMN syndrome. Some familial pre-disposition suggests a germ-line contribution to CMN
syndrome, as does variability of neurological phenotypes in individuals with similar cutaneous phenotypes.
Accordingly, we performed exome sequencing of germ-line DNA from patients with CMN to reveal rare or
undescribed Wnt-signaling alterations. A murine model harboring activated NRASQ61K and Wnt signaling in
melanocytes exhibited striking features of CMN syndrome, in particular neurological involvement. In the ﬁrst
model of treatment for this condition, these congenital, and previously assumed permanent, features were
profoundly suppressed by acute post-natal treatment with a MEK inhibitor. These data suggest that activated
NRAS and aberrant Wnt signaling conspire to drive CMN syndrome. Post-natal MEK inhibition is a potential
candidate therapy for patients with this debilitating condition.
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INTRODUCTION
Congenital melanocytic nevus (CMN) syndrome (formerly
known as neurocutaneous melanosis) is the involvement of
typically large pigmented melanocytic nevi with extra-
cutaneous features, such as certain facial characteristics and
melanotic cells within the central nervous system (CNS;
Barkovich et al., 1994; Kinsler et al., 2008; Kinsler et al.,
2012). Pigmented hairy nevi can cover up to 80% of the body
surface area, and neurological abnormalities can lead to
intractable seizures and neurodevelopmental delay. There is
also a signiﬁcant risk of primary melanoma within the skin,
brain, or leptomeninges (Krengel et al., 2006; Kinsler et al.,
2009). Previous work has shown that CMN syndrome is
caused, in roughly 80% of cases, by a single post-zygotic
mutation of NRAS codon 61 in a neuro-ectodermal precursor
(Kinsler et al., 2013b). However, some familial pre-disposition
also suggests a germ-line contribution to the development of
CMN (Danarti et al., 2003; Kinsler et al., 2009; de Wijn et al.,
2010). There is currently no treatment for this condition, and
where melanoma develops the outcome is almost universally
fatal. Despite recent advances in treatment of some types
of melanoma with targeted therapies, a cure for mela-
noma harboring NRAS mutation remains particularly elusive
(Shtivelman et al., 2014). Therefore, a potential treatment for
the cutaneous and extra-cutaneous features of CMN syn-
drome is most likely prior to its acquisition of additional
genetic alterations en route to melanoma.
In both CMN and acquired melanocytic nevi, nevus cells
are thought to be maintained in a proliferation arrested state
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by cellular senescence (Michaloglou et al., 2005; Gray-
Schopfer et al., 2006; Suram et al., 2012), a tumor-suppres-
sive, stable proliferation arrest triggered by activated onco-
genes and other molecular stresses (Salama et al., 2014). A
complex network of effectors enacts the senescence response,
including DNA damage signaling, activation of the pRB and
p53 pathways and, notably, repression of Wnt signaling (Ye
et al., 2007; Pawlikowski et al., 2013; Juan et al., 2014;
Salama et al., 2014). Paradoxically, however, we and others
have shown that nevus melanocytes, including in CMN, often
exhibit markers of activated Wnt signaling (Bergman et al.,
1997; King et al., 2001; Ramirez et al., 2005; Kinsler et al.,
2013a; Pawlikowski et al., 2013), and activated Wnt signaling
is able to bypass or delay senescence in mouse models
(Delmas et al., 2007; Pawlikowski et al., 2013; Juan et al.,
2014). We therefore reasoned that activated Wnt signaling, in
addition to the NRAS mutation, might inﬂuence the varied
phenotype of CMN syndrome.
RESULTS
Altered Wnt signaling in human CMN syndrome
To more directly assess the status of Wnt signaling in human
CMN, we stained such nevi for markers of activated Wnt
signaling. As shown previously (Kinsler et al., 2013a), CMN
expressed nuclear and cytoplasmic localized β-catenin. In
addition, these nevi consistently expressed cyclin D1 and
c-MYC (Figure 1) indicative of activated Wnt signaling and in
contrast to normal epidermal melanocytes that do not express
nuclear cyclin D1 and c-myc (Pawlikowski et al., 2013). We
conclude that human CMN are associated with activated Wnt
signaling.
A higher prevalence of CMN within some families suggests
a germ-line predisposition to CMN (Danarti et al., 2003;
Kinsler et al., 2009; de Wijn et al., 2010), and neurological
phenotypic variability between patients with similar cutaneous
phenotypes also supports a role for a modifying germline
genotype. Accordingly, we performed whole-exome next-
generation sequencing on DNA from peripheral white
blood cells of 32 children with extensive CMN (phenotypic
classiﬁcation in Supplementary Table S1 online). In CMN
syndrome, mutation of NRAS is a somatic event (Kinsler
et al. 2013b). Therefore, in these blood samples, NRAS is
wild type in all cases. Using the ﬁlters described in the
Supplementary Materials and Methods online to identify rare
variants in Wnt signaling pathway genes, 3,213,226 calls
were reduced to 32 variants in 26 genes that occur with a
prevalence o0.5% in control population databases and to
34 variants in 26 genes at o1% prevalence. After manually
reviewing the BAM ﬁles, 20 variants in 32 patients were
judged sufﬁciently convincing on all parameters to investigate
further, and of these 19 were conﬁrmed by Sanger sequen-
cing. One was not conﬁrmed, and one was not able to be
conﬁrmed because of lack of patient sample but was
sufﬁciently convincing on next-generation sequencing to be
included in the analyses. Genetic variation in FZD1 was seen
in six CMN patients and therefore considered a possible
undescribed SNP (pending conﬁrmation of its prevalence by
direct screening of a large control population). These 19
variants seen in 14 CMN patients are listed in Table 1. This list
includes variants in the APC, APC2, FZD6, TCF3, andWNT16
genes that are absent from control population databases.
Although functional characterization of each individual
variant is beyond the scope of the current study, this analysis
is supportive for a role for germ-line alterations of Wnt
signaling, together with somatic activation of NRAS, in the
development of extensive CMN.
Activation of Wnt signaling and NRAS recapitulates CMN
syndrome in a mouse model
On the basis of this ﬁnding, we asked whether combined
activation of NRAS and Wnt signaling in the melanocytic
lineage could drive formation of CMN syndrome in an animal
model. We therefore generated mice with either activated
NRAS (Tyr-NRasQ61K (Ackermann et al., 2005) or activated
Wnt signaling alone (Tyr-Cre Apcﬂ.ﬂ (Shibata et al., 1997)) or
both activated NRAS and Wnt signaling (Tyr-Cre Apcﬂ.ﬂ/Tyr-
NRasQ61K (Pawlikowski et al., 2013)), all under the control
of the mouse Tyr promoter to restrict altered signaling largely
to the melanocytic lineage (Delmas et al., 2003). These
mice were then examined for features characteristic of
CMN syndrome in humans, including skin hyperpig-
mentation and excessive inﬁltration of pigmented melano-
cytes into the leptomeninges and brain (Supplementary Figure
S1 online). As reported previously, Tyr-NRasQ61K mice
Melan A Cyclin D1 c-Mycβ-Catenin
Figure 1. Human congenital melanocytic nevi harbor activated Wnt signaling. Serial sections of a CMN stained for melan A, β-catenin, cyclin D1, and c-myc.
Images are representative of at least four congenital human nevi (Scale bar= 25 μm).
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exhibited an excess of melanocytes in the dermis and became
hyperpigmented with melanin within a few days of birth,
compared with either wild-type mice or Tyr-Cre Apcﬂ.ﬂ mice
(Ackermann et al., 2005; Pawlikowski et al., 2013). Strikingly,
activation of Wnt-signaling in Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K
mice greatly exacerbated the NRasQ61K-induced proliferative
expansion of melanocytes and skin melanization
((Supplementary Figure S2 online) and previously quantitated
in (Pawlikowski et al., 2013)), comparable to the cutaneous
features of extensive CMN (Supplementary Figure S1A
online). In addition, on post mortem, Tyr-Cre Apcﬂ.ﬂ/Tyr-
NRasQ61K mice, but neither Tyr-Cre Apcﬂ.ﬂ nor Tyr-NRasQ61K
mice, were found to have neurological features characteristic
of human CMN syndrome, including hyperpigmented spines
(Figure 2a and Supplementary Figure S1B online) and the
pathognomonic leptomeningeal melanosis around the spinal
cord (Figure 2b and c). In the head, the mice showed
melanosis and thickening of the leptomeninges, as well as
melanosis in olfactory bulbs and nasal turbinates (Figure 2d).
Invasion of melanin-producing cells around the spinal cord
and into the brain was also observed by MRI (Figure 2e and f
and Supplementary Figure S1C, S1D and Supplementary
Video S1 online), highly reminiscent of the malignant progres-
sion seen in patients with CMN complicated by melanoma
(Rhodes et al., 1991; Kinsler et al., 2008). The abnormal
inﬁltrating pigment-producing cells in the mice were
conﬁrmed as melanocytes based on morphology, as well as
expression of the neural crest cell marker S100 (Supplemen-
tary Figure S3 online).
Features of CMN syndrome are blocked through post-natal MEK
inhibition
As proliferative expansion of the melanocyte population in
the Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K mice was dependent on
WT
WT
WT
WT
WT
APC/RAS
APC/RAS
APC/RAS
APC/RAS
APC/RAS
APC/RAS
SC
VBVB
Sk
Sk
SC
SC
SC
Sk
B
B
B
B
SCVBVB
OB
TT
SC
Figure 2. A mouse model harboring activated RAS and Wnt signaling recapitulates human CMN syndrome. (a) Representative images of blackened spine and
head in 2-week-old Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K mice (right (representative of460 mice)) compared with wild-type mice (left). Tyr-Cre Apcﬂ.ﬂ and Tyr-NRasQ61K
were indistinguishable from wild-type mice in these respects (not shown). (b) Transverse H+E section showing melanocytic inﬁltration (melanin) into
leptomeninges of the spine of Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K mouse (right) compared with wild-type mouse (left). (c) Longitudinal H+E section showing
melanocytic inﬁltration (melanin) into leptomeninges of the brain of Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K mouse (bottom) compared with wild-type mouse (top).
(d) Melanocytic inﬁltration of cartilage and the olfactory system of Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K mouse. (e) Longitudinal MRI showing melanocytic invasion
(white) into the head in Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K mouse (bottom) compared with wild-type mouse (top). (f) Longitudinal MRI showing melanocytic invasion
(white) around spine in Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K mouse (right) compared with wild-type mouse (left). Blue arrows indicate melanocytic inﬁltration.
APC, adenomatous polyposis coli; B, Brain; CMN, congenital melanocytic nevus; MRI, magnetic resonance imaging; OB, Olfactory Bulb; SC, spinal cord;
Sk, Skull; T, Turbinates; VB, vertebral body; WT, wild type.
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dual activation of NRAS and Wnt signaling, we reasoned that
inhibition of NRAS signaling alone should be sufﬁcient to
inhibit proliferation of these cells. To test this in vitro, we
prepared cutaneous melanocytes from Tyr-Cre Apcﬂ.ﬂ/Tyr-
NRasQ61K mice. These genetically altered cells were highly
pigmented and showed a dendritic morphology, character-
istic of melanocytes (Figure 3a). To test the inﬂuence of
reducing activity of the MAPK/ERK pathway, we treated
Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K mouse melanocytes in vitro with
the allosteric MEK inhibitor, AZD6244 (selumetinib, ARRY-
-142886; Yeh et al., 2007). Upon MEK inhibition, prolife-
ration was signiﬁcantly reduced, as measured by a decrease
in EdU incorporation and suppression of cyclin A expression
(Figure 3b–d).
A massive expansion of melanocytes in the skin of Tyr-Cre
Apcﬂ.ﬂ/Tyr-NRasQ61K mice occurs predominantly within the
ﬁrst 2 weeks of life (Pawlikowski et al., 2013). Therefore, we
reasoned that treatment of such neonatal mice with a MEK
inhibitor over the ﬁrst 2 weeks of life could potentially
decrease melanocytic proliferation and suppress features of
CMN syndrome. Mice were treated three times weekly by
intraperitoneal injection with AZD6244 or DMSO vehicle for
2 weeks after birth (Figure 4a). PhosphoERK staining in the
liver was markedly decreased, conﬁrming that this regimen
effectively inhibited MEK–ERK signaling in the mice
(Supplementary Figure S4 online). Treatment with AZD6244
greatly reduced the population of melanocytes in the skin
dermis (Figure 4b) compared to vehicle and, crucially,
signiﬁcantly decreased numbers of melanocytes in the CNS
(Figure 4c and d). Indicative of at least partial sustained
beneﬁt from drug treatment, acute post-natal treatment with
AZD6244 over 2 weeks, followed by withdrawal from
therapy, resulted in a signiﬁcant decrease in pigmentation
within the CNS 4 weeks after the end of drug treatment
(Figure 5).
DISCUSSION
Here we present several lines of evidence to indicate that, in
at least a subset of cases of human CMN syndrome, the
phenotype is likely to be driven by concerted aberration of
NRAS and Wnt signaling. First, by whole-exome sequencing
we identiﬁed a number of sequence variants in genes of the
Wnt signaling pathway in DNA of peripheral white blood
cells. Several of these variants are to our knowledge
previously unreported, and those described are detected only
at extremely low frequency in published databases. All are
predicted to impair the function of the encoded protein,
where in silico prediction is possible. Given the complexity of
the Wnt signaling pathway, comprising positive and negative
regulators and antagonistic interactions between canonical
Wnt/β-catenin signaling and the non-canonical Wnt pathway
(Niehrs, 2012), it is difﬁcult to conﬁdently ascertain whether
these variants activate or inhibit Wnt/β-catenin signaling,
without extensive additional functional studies. At this time,
these sequence variants are good candidates for heritable,
germ-line variants that alter activity of the Wnt signaling
pathway, which we postulate may have a synergistic effect in
the presence of a somatic NRAS mutation. Second, we
observed that human CMN exhibit markers of activated Wnt
signaling, suggesting that the effect of activated Wnt is not
only important in the congenital development of the disease
but may be involved in the post-natal persistence of the
nevus. Third, in a mouse model that to our knowledge is
previously unreported, we showed that melanocyte-speciﬁc
activated NRASQ61K and activated Wnt signaling, through
inactivation of APC, cooperate to generate features of
CMN syndrome, most notably a massive excess of melano-
cytes in the skin and inﬁltration of melanocytes into the
leptomeninges and CNS. Finally, post-natal systemic treat-
ment with a MEK inhibitor, an inhibitor of NRAS signaling,
reversed both the cutaneous and neurological features of this
mouse model.
Previous reports have described other genetically modiﬁed
mice exhibiting phenotypes that partially resemble CMN
syndrome. Merlino and coworkers showed that constitutive
expression of Scatter factor/hepatocyte growth factor under
control of the mouse metallothionein I promoter induced
melanosis in the CNS and hyperpigmentation in the skin
(Takayama et al., 1996). Although we cannot exclude a
role for Scatter factor/hepatocyte growth factor signaling
in CMN syndrome, this model does not recapitulate the
most common hallmark of human CMN syndrome, NRAS
codon 61 mutation (Kinsler et al., 2013b). Several groups
Vehicle
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Figure 3. Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K mouse melanocytes are sensitive to
MEK inhibition in vitro. (a) Phase contrast image of dendritic, pigmented
melanocytes isolated from the skin of Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K mouse
(Scale bar = 25 μm). (b) MEK inhibitor, AZD6244, downregulates
phosphoERK and cyclin A expression. Cells were treated with DMSO vehicle
or AZD6244, as indicated. (c) EdU labeling and DAPI stain of nuclei from b
(Scale bar= 25 μm). (d) Quantitation of EdU labeling from (c). Results from
three experiments, each scoring 4100 DAPI-stained nuclei. Linear mixed-
effects model was performed to compare the difference in percent EdU
positive.
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have previously reported hyperpigmentation in the skin
of mice expressing NRasQ61K in the melanocyte lineage
(Ackermann et al., 2005; Delmas et al., 2007; Shakhova et al.,
2012). However, consistent with our observations, none of
these groups reported any neurological involvement. One of
these studies found that a stabilized β-catenin allele coope-
rated with NRasQ61K to promote melanoma (Delmas et al.,
2007). However, these melanomas were proposed to arise
from the hair follicle bulb or the bulge region in the skin. As
discussed previously (Pawlikowski et al., 2013), we have not
observed any frank melanoma in Tyr-Cre Apcﬂ.ﬂ/Tyr-
NRasQ61K mice, likely because the behavioral and neuro-
logical abnormalities associated with CNS inﬁltration,
themselves characteristic of CMN syndrome (Barkovich
et al., 1994; Kinsler et al., 2009; Kinsler et al., 2008),
preclude keeping any live mice beyond 4 months for ethical
reasons.
Marais and coworkers reported in a murine model that
expression of NRASG12D in the melanocyte lineage induced
melanocyte proliferation and congenital melanocytic
skin lesions and also primary melanoma of the CNS of
variable latency but high penetrance (Pedersen et al., 2013).
Human CMN syndrome, however, is typically characterized
by mutation of NRAS at codon 61, not codon 12 (Kinsler
et al., 2013b), although a uncommon variant of CMN is rarely
associated with codon 13 mutations (Kinsler et al., 2014),
with a single case report of brain involvement in a patient
with p.G13R (Shih et al., 2014). In addition, the most
common congenital CNS ﬁnding is melanosis in the paren-
chyma or the leptomeniges, with intracerebral primary
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times per week for 2 weeks) with vehicle or AZD6244. Two weeks later, mice were euthanized and tissues were harvested and processed. (b) S100 stained skin
sections from Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K mice treated with vehicle (left) compared with AZD6244 treatment (right). (c) Representative images showing dorsal
view of Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61K mice treated with vehicle (left) or AZD6244 (right), after removal of the skin. (d) (Left) Quantitation of percent melanization
in (c) along length of mouse from anterior of brain (0.0) to posterior of spine (1.0); (right) magniﬁed portion of boxed region of left. Seven mice of each group with
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melanoma being a more rare and acquired phenomenon.
Thus, the Tyr-Cre Apcﬂ.ﬂ/Tyr-NRasQ61Kmice reported here
appear, to date, to be the best combined genetic and
phenotypic recapitulation of human CMN syndrome.
The idea that CMN syndrome results from activated NRAS
and Wnt signaling extends the model previously proposed for
human acquired melanocytic nevi. Speciﬁcally, their formation
is thought to depend on activated NRAS or BRAF signaling, due
to oncogenic mutation of NRAS or BRAF (Omholt et al., 2002;
Pollock et al., 2003), and also depends on input from the Wnt
signaling pathway (Pawlikowski et al., 2013). Normal human
melanocytes are exposed to activated Wnt signaling as they
migrate from the neural crest to the epidermis (Ikeya et al.,
1997; Dorsky et al., 1998; Dunn et al., 2000), and this might
be the source of Wnt signaling for benign nevogenesis
(Pawlikowski et al., 2013), either congenital in utero or
acquired, which typically occurs in young children (Bataille
et al., 2007; Zalaudek et al., 2011). In some cases of CMN
syndrome, we propose that somaticNRASmutation cooperates
with a higher level of sustained Wnt signaling resulting from
germ-line genetic variants or other activators of the Wnt
pathway to drive a much more severe melanocytic expansion.
This germ-line modiﬁer could provide a possible explanation
for the unexplained observation of the presence or absence of
neurological involvement in unrelated CMN syndrome indivi-
duals with the same cutaneous phenotype––a clinical problem
that leads to all children with multiple CMN having MRI
screening of the CNS in the ﬁrst few months of life (Waelchli
et al. 2015). Additional studies are required to conﬁrm the
functional signiﬁcance of these variants in the pathogenesis of
CMN syndrome.
Alterations of Wnt signaling in pediatric pathologies are not
exclusive to CMN syndrome. For instance, more than half of
all pediatric Wilms’ tumor (the fourth most common child-
hood malignancy) have been reported to showWnt activation
(Su et al., 2008). In the mouse, activation of KRAS and
stabilization of β-catenin, speciﬁcally in the developing
kidney, cause metastatic renal epithelial tumors to develop
that mimic the epithelial component of Wilms’ tumor (Clark
et al., 2011). As in CMN syndrome, the molecular basis of
Wnt signaling activation driving this disease is often unclear
(Su et al., 2008). With a greater understanding of the cross-talk
between RAS and Wnt signaling in benign and advanced
disease, we may better decipher the inner workings of
multiple childhood malignancies.
An understanding of the genetic basis of CMN syndrome is
a likely ﬁrst step to therapeutic interventions. On the basis of
our previous ﬁnding that CMN syndrome is caused by
somatic NRAS mutation (Kinsler et al., 2013b), a recent
report administered an oral MEK inhibitor to a 13-year-old
boy with CMN syndrome in the very advanced stages of
leptomeningeal melanoma (Kusters-Vandevelde et al., 2014).
Despite biomarker responses to the drug, the child passed
away within days, as would be expected from the natural
history of this malignancy at this stage. As onset of melanoma
in CMN is known to require further key mutations affecting
proliferative pathways (Kinsler et al., 2013b), intervention
before progression to malignancy is likely to be the key to
success. In support of further testing of this approach, here we
report that acute post-natal inhibition of MEK–ERK signaling
downstream of NRASQ61K does substantially rescue the key
features of CMN syndrome in this mouse model, speciﬁcally
the massive expansion of melanocytes in the skin, brain, and
leptomeninges. These results suggest that MEK inhibitors,
currently Food and Drug Administration–approved or being
trialed for use in melanoma (Sullivan and Flaherty, 2013),
might also beneﬁt patients with CMN syndrome. Importantly,
although the cure of advanced melanoma through application
of targeted therapies, such as MEK and BRAFV600E inhibitors
(Shtivelman et al., 2014), has ultimately been frustrated often
by acquisition of drug resistance, conceivably this might not
be a confounding factor in CMN syndrome with its many
fewer genetic alterations.
MATERIALS AND METHODS
Additional details of Materials and Methods are available in
Supplementary Materials and Methods online.
Human tissues
Congenital melanocytic nevi were obtained under an Institutional
Review Board approved protocol by a board-certiﬁed dermato-
pathologist (HWM) from Fox Chase Cancer Center, Philadelphia.
These tissues were ﬁxed in 10% (vol/vol) buffered formalin for
1–3 days and embedded in parafﬁn, following routine histology
procedure.
For whole-exome sequencing, peripheral blood leukocyte DNA
was extracted from samples from 32 children with CMN attending a
specialist clinic at Great Ormond St Hospital, London. Written
consent was obtained in all cases, and the study was approved by the
Great Ormond Street Hospital/UCL Institute of Child Health Research
Ethics Committee. Detailed phenotyping of the cutaneous and
neurological signs of the participants is shown in Supplementary
Table S1 online, demonstrating that this group is at the severe end of
the phenotypic spectrum of individuals with CMN.
Immunoblotting
Cells were lysed in 1× Laemmeli sample buffer, and 30–50 μg of
protein was resolved by SDS-polyacrylamide gel electrophoresis
followed by transfer onto PVDF membrane and probing with
antibodies. Antibodies used include the following: anti-cyclin A
(SC-754, Santa Cruz Biotechnology, Dallas, TX), anti-β-actin (A1978,
Sigma, St. Louis, MO), p44/42 MAPK (Erk1/2, 4695, Cell Signaling,
Danvers, MA) and phospho-p44/42 MAPK (Erk1/2, Thr202/Tyr204,
9101, Cell Signaling), anti-rabbit IgG, horseradish peroxidase-linked
(NA934, GE Healthcare, Fairﬁeld, CT), and anti-mouse IgG, horse-
radish peroxidase-linked (P0447, Dako, Carpinteria, CA).
Cell proliferation assays, immunoﬂuorescence
The Click-iT EdU Alexa Fluor 594 Imaging Kit (C10339, Life
Technologies, Carlsbad, CA) was used according to the manufac-
turer’s instructions to monitor cellular proliferation.
Immunohistochemistry
Brieﬂy, formalin ﬁxed, parafﬁn embedded sections were deparafﬁ-
nised, rehydrated, blocked for endogenous peroxidases, and under-
went antigen retrieval according to antibody speciﬁcations. Tissues
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were incubated overnight with the following primary antibodies:
Anti-human melan-a clone A103 (Dako, M7196), S100 (Dako,
Z0311), β-catenin (610154, BD Transduction Laboratories, San Jose,
CA), CyclinD1 clone EP12 (Dako, M3642), c-myc clone 9E10 (Santa
Cruz Biotechnology, sc-40), p44/42 MAPK (Erk1/2; Cell Signaling,
4695) and phospho-p44/42 MAPK (Erk1/2, Thr202/Tyr204, Cell
Signaling, 9101), mouse IgG (I-2000, Vector, Burlingame, CA), and
rabbit IgG (Vector, I-1000). Secondary antibodies used for DAB-
based IHC were either EnVision+ System- horseradish peroxidase
Labeled Polymer Anti-mouse (Dako, K4001) or EnVision+ System-
horseradish peroxidase Labeled Polymer Anti-rabbit (Dako, K4003)
based on primary antibody host species. Peroxidase activity was
revealed using DAB (Dako, K3468). Samples were then counter-
stained with haematoxylin, dehydrated, and coverslipped.
Genetically modiﬁed mice
Tyr-NRasQ61K mice and Apcﬂ.ﬂ mice were mated to Tyr-Cre mice
(Shibata et al., 1997; Delmas et al., 2003; Ackermann et al., 2005).
Progenies from these crosses were then interbred to obtain Tyr-Cre
Apcﬂ.ﬂ/Tyr-NRasQ61K and were maintained on a C57BL6 back-
ground. Mice were kept in conventional animal facilities, monitored
frequently, and experiments were carried out in compliance with UK
Home Ofﬁce guidelines at the Beatson Institute for Cancer Research
mouse facility (Home Ofﬁce PCD 60/2,607) under project license
60/4,079. Mice were genotyped by Transnetyx. Mice were ﬁrst
treated at their day of birth or at 1 day of age with AZD6244
(10mg kg−1) or DMSO vehicle via intraperitoneal injection and
then three times per week for 2 weeks. Mice were euthanized
following a Schedule 1 method, and tissues were collected for
histological analyses.
Whole-exome sequencing
Whole-exome sequencing was performed in two batches of 23
and 10 samples. For the ﬁrst batch, a total of 3 μg of DNA was
used to prepare a DNA library using Covaris DNA sonication
and NEB NEBNext DNA Sample Prep Reagent Set 1 (E6000S, New
England Biolabs, Ipswich, MA). DNA fragments containing adaptors
were enriched by PCR (four cycles). Samples were processed using
SureSelect target Enrichment System for Illumina Paired-End Sequen-
cing Library (Protocol version 2.0.1 May 2010). Puriﬁed libraries
were checked for quality throughout the process and quantiﬁed using
an Agilent (Santa Clara, CA) 2,100 Bioanalyser. Samples were
sequenced using Illumina (San Diego, CA) Solexa chemistry on a
Genome Analyzer IIx. Illumina 76 bp paired end kits were used
according to the manufacturer’s protocol. For the second batch,
paired-end library preparation was by Illumina Nextera Rapid
Capture Enrichment (protocol June 2013) using 50 ng DNA and
sequenced on an Illumina HiSeq 2,000. Sequences were analyzed as
described in Supplementary Materials and Methods online.
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